QUALITY, PRODUCT SUPPLY, AND TECHNOLOGY COMMITTEE CHARTER

Inspire Medical Systems, Inc.

(Adopted: February 6, 2025)

1.0 Purpose

The purposes of the Quality, Product Supply, and Technology Committee (the "Committee") of the Board of Directors (the "Board") of Inspire Medical Systems, Inc. (the "Company"), are to carry out the responsibilities of the Board relating to oversight of (a) the quality, safety, and supply of the Company's products, (b) the Company's compliance with legal and regulatory requirements and the Company's Code of Business Conduct and Ethics (the "Code of Conduct") and related compliance policies, and (c) the Company's research, innovation, and technology initiatives and programs. The Committee will coordinate with the Audit Committee through each committee's respective committee chair in monitoring compliance by the Company with legal and regulatory requirements and oversight of related risk management programs and activities. Nothing in this Charter shall relieve the Audit Committee of its obligations under applicable law or the rules of the New York Stock Exchange ("NYSE").

2.0 Composition

The Committee must consist of at least three directors, each of whom must satisfy the independence requirements of the NYSE. Committee members must be appointed and may be removed, with or without cause, by the Board. The Chair of the Committee will also be designated by the Board.

3.0 Meetings, Procedures and Authority

The Committee has the authority to establish its own rules and procedures for notice and conduct of its meetings so long as they are not inconsistent with any provisions of the Company's bylaws or corporate governance guidelines that are applicable to the Committee.

The Committee has the authority to retain any independent counsel, experts or advisors that the Committee believes to be desirable and appropriate and has the authority to approve related fees and retention terms.

In addition to the duties and responsibilities expressly delegated to the Committee in this Charter, the Committee may exercise any other powers and carry out any other responsibilities consistent with this Charter, the purposes of the Committee, and the Company's bylaws.

4.0 Duties and Responsibilities

The duties and responsibilities of the Committee, on behalf of the Board, shall include the following:

1. *Product Quality, Safety, and Supply*. The Committee will oversee risk management of product quality, safety, and supply matters, including the following:

    - The Company's overall strategy and systems in place to monitor the quality and safety of the Company's products throughout the product life cycle (including research and development, manufacturing, marketing and promotion,

distribution and supply, use, and end-of-life);

- The Company's quality management systems ("QMS"), related policies and procedures, and internal and external QMS assessments and audits;
- Significant product complaints, medical device reports and other adverse event reporting, field corrective actions, product recalls, and corrective and preventative actions;
- Inspections by the Food and Drug Administration (the "FDA") and other similar state, local, and foreign agencies, and compliance with warning letters and other similar government directives;
- Supply chain and operational risks;
- Employee training and education programs addressing product quality and safety; and
- The Company's management of any other significant product quality, safety, and supply risks and issues.

2. *Compliance and Ethics*. The Committee shall oversee the Company's compliance and ethics program, including the Company's compliance with healthcare legal and regulatory requirements (including laws, rules, and regulations administered by the FDA, requirements of U.S. federal healthcare programs, requirements of anti-kickback, anti-inducement, and other fraud and abuse laws, false claims laws, the Health Insurance Portability and Accountability Act of 1996, the Physicians Payments Sunshine Act, and any equivalent healthcare legal and regulatory requirements administered by state, local, or foreign agencies), regulatory submissions and registrations, compliance with the Code of Conduct and related compliance policies and programs, and compliance with other legal and regulatory requirements applicable to the Company's operations or products globally. The Audit Committee shall have primary oversight responsibilities as to matters of financial compliance, including compliance matters related to the Company's accounting practices, internal accounting controls, auditing matters, and questionable financial practices.

3. *Research, Innovation, and Technology*. The Committee will oversee the Company's research, innovation, and technology initiatives and programs, including the Company's research and development activities, innovation and technology strategy, product and therapy development pipeline, clinical trials and related activities, intellectual property portfolio, and review and approval process with the FDA and similar state, local, and foreign agencies.

4. *Strategic Transactions*. The Committee will, from time to time as it deems appropriate, review with management the Company's strategy and opportunities for new ventures, investments, acquisitions, and other strategic transactions.

5. *Code of Business Conduct and Ethics*. The Committee will, from time to time as it deems appropriate, review and reassess the Code of Conduct and recommend any proposed changes to the Board for approval.

6. *Compliance Audits, Investigations, and Trainings*. The Committee will, from time to time as it deems appropriate, review and assess the Company's compliance with the

Code of Conduct and related compliance policies, including significant compliance-related audits and investigations conducted under the Company's compliance program, the implementation of any corrective or preventative actions taken, and the Company's compliance training and education programs.

7. *Sustainability Oversight*. The Committee will provide support to the Nominating and Corporate Governance Committee, as needed, related to the periodic review and oversight of the Company's strategy, policies, and practices and related reporting with respect to significant sustainability matters, with a focus on product quality, safety and supply, compliance, ethics, research, innovation, and technology.

8. *Enterprise Risk Management*. The Committee shall assist the Board and the Audit Committee in its oversight of the Company's enterprise risk management program with respect to risks in the Committee's areas of oversight and as outlined in this Charter. The Audit Committee shall oversee the Company's overall enterprise risk management program.

9. *Reports to the Board of Directors*. The Committee must report regularly to the Board regarding the activities of the Committee.

10. *Committee Self-Evaluation*. The Committee must at least annually perform an evaluation of the performance of the Committee.

11. *Review of this Charter*. The Committee must annually review and reassess this Charter and submit any recommended changes to the Board for its consideration.

5.0 Delegation of Duties

In fulfilling its responsibilities, the Committee has the authority to delegate any or all of its responsibilities to a subcommittee of the Committee.